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transition by targeting QKI-5 in esophageal
squamous cell carcinoma
Zhenyue He1†, Jun Yi2†, Xiaolong Liu2†, Jing Chen1, Siqi Han1, Li Jin1, Longbang Chen1* and Haizhu Song1*
Abstract
Background: Dysregulation of microRNAs (miRNAs) have been demonstrated to contribute to carcinogenesis.
MiR-143-3p has been identified to function as a tumor suppressor in several tumors, but the role of miR-143-3p in
esophageal squamous cell carcinoma (ESCC) has not been intensively investigated. Our aim was to evaluate the
potential role of miR-143-3p in the progression of ESCC.
Methods: The expression levels of miR-143-3p and QKI-5 protein were measured in 80 resected ESCC tumor
specimens and the clinicopathological significance of these levels determined. We also investigated the role of
miR-143-3p in the regulation of QKI-5 expression in ESCC cell lines both in vivo and in vitro.
Results: MiR-143-3p levels were decreased in ESCC clinical samples and low expression of miR-143-3p was significantly
associated with poor prognosis in ESCC patients. Ectopic expression of miR-143-3p suppressed proliferation and induced
apoptosis in ESCC cells both in vivo and in vitro. Ectopic expression of miR-143-3p also reduced the metastatic potential
of cells by selectively regulating epithelial–mesenchymal transition regulatory proteins. Furthermore, QKI-5 isoform was
upregulated in ESCC tissues and was a direct target of miR-143-3p. Lastly, re-introduction of QKI-5 expression abrogated
the inhibitory effects of miR-143-3p on ESCC cell proliferation and motility.
Conclusions: Our results demonstrate that miR-143-3p acts as a tumor-suppressor by targeting QKI-5 in ESCC, suggesting
that miR-143-3p is a potential therapy for the treatment of ESCC.
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Background
Esophageal cancer (EC) is the eighth-most common can-
cer with a highly aggressive potency, and the sixth lead-
ing cause of cancer-related mortality worldwide [1]. The
two main types of EC are esophageal adenocarcinoma
(EA) and esophageal squamous cell carcinoma (ESCC),
and each disease possesses distinct histopathological
features and clinical behaviors. ESCC is the most
frequent subtype of EC, with EA less common in China.
Epidemiological study indicates that the incidence and
histological subtypes of EC are associated with environ-
mental, genetic and epigenetic factors [2]. No typical
symptoms suggestive of ESCC exist until disease is ad-
vanced, conferring difficulty upon early diagnosis of
ESCC. Moreover, the limited medical and surgical treat-
ment options for patients diagnosed at a later stage
underpin a poor prognosis with a 5-year overall sur-
vival rate of 15–25 % [3]. Exploration of the molecu-
lar mechanisms that promote ESCC development and
progression could improve the diagnosis, therapy, and
prevention of this disease.
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MicroRNAs (miRNAs) are endogenous non-coding
RNAs of 18–22 nucleotides in length that regulate gene
expression by complementary binding to the 3’-untrans-
lated regions (3’-UTR) of specific mRNA targets [4, 5].
Accumulating evidence suggests that dysregulated miR-
NAs can function either as oncogenes or tumor suppres-
sor genes to affect the initiation and progression of
tumors, including ESCC [6–9]. A previous study identi-
fied miR-21 upregulation in ESCC cell lines and tissues,
with increased miR-21 promoting cell proliferation and
invasion by targeting PTEN and PDCD4 [10]. Another
study has revealed that miR-145, miR-133a and miR-
133b suppressed tumor proliferation by regulating the
oncogenic actin-binding protein, FSCN1 [11].
The QKI protein belongs to the signal transduction
and activation of RNA (STAR) protein family and is a
key post-transcriptional regulator. QKI expresses three
major alternatively spliced mRNAs: QKI-5, QKI-6 and
QKI-7. QKI-5 is the only nuclear isoform and shuttles
between the nucleus and cytoplasm [12], whereas QKI-6
is distributed throughout the cell and QKI-7 is cytoplas-
mic [13]. These QKI proteins selectively interact with
the QKI response element and function in various as-
pects of RNA processing [14, 15]. Aberrant expression
of QKI-5 is associated with the development and
progression of human cancers. For example, QKI-5
functions as a tumor suppressor gene in prostate cancer
[16] and colon cancer [17]. However, the potential role
for QKI-5 in ESCC proliferation and metastasis has not
been described.
Our present study demonstrates that miR-143-3p, a
miRNA species that is downregulated in ESCC tissues
and cell lines, inhibits the development and metastasis
of ESCC cells both in vivo and in vitro. Specifically, our
study reports for the first time that QKI-5 is a direct tar-
get of miR-143-3p in ESCC. MiR-143-3p-dependent
downregulation of QKI-5 inhibited cell proliferation, mi-
gration, and invasion of ESCC cells. These findings indi-
cate that the miR-143-3p/QKI-5 axis is an important
regulator of the development and progression of ESCC
and provides a candidate target for ESCC treatment.
Methods
Cell culture and tissue samples
The human normal esophageal epithelial cell line HEEC
and human ESCC cell lines (Kyse30, Kyse70, Eca109,
and Ec9706) were purchased from the Cell Bank of
Shanghai Institute of Cell Biology (Chinese Academy of
Medical Sciences, Shanghai, China). HEEC, Kyse30,
Kyse70, and Eca109 cells were expanded in RPMI-1640
medium (Gibco, USA) supplemented with 10 % fetal
bovine serum (FBS, Gibco, USA) and 1 % penicillin/
streptomycin (Invitrogen, Shanghai, China). Ec9706 cells
were grown in Dulbecco’s modified eagle’s medium
(DMEM, Gibco, USA) supplemented with 10 % FBS and
1 % penicillin/streptomycin. Cells were all cultured at
37 °C in a 5 % CO2 -humidified incubator.
Pairs of primary ESCC and adjacent normal tissue speci-
mens (n = 80) were obtained from the Cardiothoracic
Surgery Department of Jinling Hospital (Jiangsu, China).
None of the patients with ESCC had received radiotherapy
or chemotherapy before surgery. The research protocol
was reviewed and approved by the Ethical Committee and
Institutional Review Board of the Jinling Hospital, and
written informed consent was obtained from each patient
included in the study.
MiRCURY LNA array analysis
Total RNA was extracted from five pairs of ESCC tumor
and adjacent normal tissues using the mirVana miRNA
isolation kit (Ambion, USA). Microarray chip analysis was
performed and analyzed by Exiqon (Vedbaek, Denmark).
The fold-change was calculated by comparing the expres-
sion level of miRNAs in the ESCC tumor pool and with
that of the normal tissue pool using a log2 format.
miRNA target prediction
Five established miRNA-target prediction programs
(TargetScan, miRanda, PicTar, MirTarget2, and PITA)
were employed to predict miRNA targets, with genes
predicted by all five independent tools considered. The
selected genes of each individual miRNA were subjected
to GO and pathway analysis.
Plasmid and cell transfection
We selected Kyse30, Kyse70, and Eca109 cells for further
functional research. Plasmids encoding miR-143-3p,
anti-miR-143-3p and their corresponding controls (miR-
NC and anti-miR-NC) were purchased from ABM
(ABM, Canada). For the reduction and induction of
QKI-5 expression, GFP-tagged of human pLenti QKI-5,
pLenti siQKI-5 and matched controls (pLenti-Blank and
Scrambled siRNA) plasmids were also purchased from
ABM (ABM, Canada). Cells were transfected with plas-
mids using DNAfectin Plus (ABM, Canada) according to
the manufacturer’s protocol. Stably-transfected cells
were selected for 14 days in the presence of 2 μg/mL
puromycin (Sigma, USA).
Western blot analysis
Cells and tissues were lysed with ice-cold RIPA buffer sup-
plement with Phenylmethanesulfonyl Fluoride (PMSF) and
cocktail. Total protein concentrations were measured using
the KeyGEN BCA Protein Quantitation Assay (KeyGEN,
China). Cell lysates were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred
onto polyvinylidene fluoride membranes. Membranes were
incubated with the following primary antibodies overnight
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at 4 °C: rabbit anti-human QKI antibody (Bethyl, USA),
epithelial-mesenchymal transition antibody (Cell Signaling,
USA), and mouse anti-human GAPDH antibody (Cell
Signaling, USA). Membranes were then incubated with
horseradish peroxidase-conjugated goat anti-rabbit or goat
anti-mouse antibody for 1 h at 37 °C. Immunoreactive
bands were visualized using an enhanced ECL system
(Thermo Scientific, USA) and the blots were exposed to
Kodak X-ray film. Quantification of western blots was ob-
tained by multiplying the area and intensity of each band
using Image J software.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue specimens were
sectioned into 3–4 μm sections for immunohistochemis-
try. Sections were then treated with xylene, and hydrated
through a series of decreasing concentrations of ethanol
to water. For antigen retrieval, slides were incubated with
citrate buffer solution (Maixin Bio, China) at 100 °C for
1 min. Slides were then immersed in 100 μl 3 % hydrogen
peroxide for 10 min at room temperature, and the tissue
sections incubated with primary antibody at 4 °C
overnight. Subsequently, the sections were incubated with
secondary antibody for 60 min at 37 °C. Last, diaminoben-
zidine was used as the colorizing reagent, and hematoxylin
was used to counter stain nuclei.
Stained sections were scored by three pathologists in-
dependently and interobserver agreement reached. Each
section was scored according to the intensity and per-
centage of positive cells. Staining intensity was scored as
follows: 0 (negative), 1 (weakly positive), 2 (moderately
positive), and 3 (strongly positive). The percentage of
positive cells was also graded according to four categor-
ies, 1 point for 0–25 % positive cells; 2 for 26–50 % posi-
tive cells; 3 for 51–75 % positive cells; and 4 for more
than 75 % positive cells. Overall scores ≤ 3 were defined
as negative, and scores > 3 were defined as positive.
RNA extraction, reverse transcription, and real-time
quantitative RT-PCR
Total RNA was extracted from surgical tissue specimens
and cell lines using TRIzol reagent (Takara, Japan) ac-
cording to the manufacturer’s instructions. For miRNA
reverse transcription, cDNA was synthesized using the
miRNA cDNA Synthesis Kit (ABM, Canada). For mRNA
reverse transcription, cDNA was synthesized using 5×
All-In-One RT MasterMix (ABM, Canada). Real time
quantitative RT-PCR was performed using EvaGreen
miRNA qPCR Mastermix-ROX and EvaGreen 2× qPCR
MasterMix-ROX (ABM, Canada) according to the
manufacturer’s instructions. Relative quantification was
achieved by normalization to the amount of U6 (abbre-
viation of RNU6B) or GAPDH mRNA. All reactions
were performed in triplicate. The primers for miR-143-
3p and U6 were purchased from ABM. The primers for
GAPDH were 5’-GCACCGTCAAGGCTGAGAAC-3’
and 5’-TGGTGAAGACGCCAGTGGA-3’. The primers
for QKI-5, QKI-6, and QKI-7 have been described previ-
ously [18]. Relative gene expression levels were calcu-
lated by the ΔΔCt method.
Cell proliferation assay
Cell proliferation was analyzed using the 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay. In total, 5 × 103 transfected cells were
seeded into each well of a 96-well plate and cultured for
1–3 days, followed by addition of MTT solution to the
cells for 4 h. After removing the medium, the remaining
MTT formazan crystals were solubilized in DMSO and
absorbance was measured using a microplate reader at
490 nm.
Colony formation assay
Transfected cells were seeded into six-well plates in trip-
licate (500 cells/well). Cells were allowed to grow for
10–14 days. To visualize colonies, cells were fixed with
methanol and stained with 0.1 % crystal violet. Colonies
with ≥ 50 cells were manually counted under a dissection
microscope.
Apoptosis assay
Cell apoptosis analysis was performed using an Annexin
V-FITC/PI Apoptosis Detection Kit (Oncogene Research
Products). Approximately 48 h after transfection, cells
were digested with trypsin, washed twice with PBS, and
then resuspended in the binding buffer. Annexin V-
FITC and propidium iodide (PI) were then added.
Finally, apoptosis was assessed by flow cytometry. The
degree of apoptosis in tissue was also quantified using a
TUNEL kit (Roche, Shanghai, China) according to the
manufacturer’s instructions.
In vitro migration and invasion assays
The wound healing assay was performed to assess cell
migration ability. 5 × 105 transfected cells were seeded
into six-well plates. After serum starvation in serum-free
medium for 24 h, an artificial wound was created on the
confluent cell monolayer using a standard 200 μL plastic
pipette tip. Cells migrated into the scratch area as single
cells from the confluent sides, and the width of the
scratch gap was viewed under an inverted microscope
and photographed at 0 h and 48 h. Three replicates of
each condition were used.
For the Transwell migration assay, the above trans-
fected cells were plated to the upper chambers of 8-μm
pore size Transwell plates (Corning, MA, USA). For the
Matrigel-coated Transwell invasion assay, Matrigel and
transfected cells were plated to the upper chambers of
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Transwell plates. All experiments were performed at
least three times in triplicate. Approximately 24 h after
seeding, cells that appeared on the undersurface of the
filter were fixed with methanol, stained with 0.1 % crys-
tal violet and counted under a microscope.
Luciferase reporter assay
The luciferase reporter assays was conducted according
to the manufacturer’s instructions (Promega, USA). Each
sample was measured in triplicate, and the experiment
was repeated at least three times. The transfection
efficiency was measured by cotransfection with a Renilla
luciferase expression plasmid pRL-SV40 (Promega, USA)
and the luciferase activity was measured using the Dual-
Luciferase Reporter Assay System (Promega, USA).
Mice xenograft models and immunohistochemistry
analysis
This study and all experimental protocols were approved
by the authors’ institutional review board. Age-matched
BALB/C nude mice were obtained from the Department
of Comparative Medicine in Jinling Hospital. Approxi-
mately 5 × 106 Kyse70 cells were suspended in 100 μL
PBS and inoculated subcutaneously into the right side of
the posterior flank of the mice. Beginning day 6 after in-
jection, tumor diameters were measured every other day.
After 18 days, all mice were killed, and necropsies were
performed. Tumor volume was calculated using the
equation: V = A × B2/2 (mm3), where A is the largest
diameter and B is the perpendicular diameter. The pri-
mary tumors were excised and analyzed by immunohis-
tochemistry and TUNEL staining.
Statistical analysis
The categorical variables of the 80 clinical specimens
examined were compared using the chi-square test.
Survival analysis using the Kaplan-Meier method was
performed using the log-rank test. The relationship be-
tween two variables and numerical values obtained by
real-time quantitative RT-PCR were analyzed using
Student’s t-tests. Multiple group comparisons were ana-
lyzed with one-way ANOVA. Statistical significance was
defined as P <0.05. All statistical analyses were performed
using SPSS18.0 software (SPSS Inc., USA).
Results
MiR-143-3p is frequently downregulated in ESCC cell lines
and tissues
The roles of miRNA in ESCC were investigated by using
miRCURY LNA array analysis to compare miRNA expres-
sion profiles between ESCC tumors and matched adjacent
normal tissue specimens from five primary ESCC cases
treated by the Cardiothoracic Surgery Department of
Jinling Hospital. After global normalization of the raw
data, 28 differentially expressed miRNAs were identified
in ESCC tumor tissues compared with their normal tis-
sues when using a 50-fold change cut-off point (Table 1).
These included 21 highly-expressed miRNAs and seven
lowly-expressed miRNAs.
We further validated the microarray results by detect-
ing the expression levels of the three most downregu-
lated miRNAs (miR-143-3p, miR-133b, miR-143-5p) in
the HEEC cell line and four ESCC cell lines. Figure 1a
reveals that miR-143-3p exhibited the largest absolute
fold-change in the expression in ESCC cell lines. We
further measured the expression of miR-143-3p in 80
pairs of primary ESCC tissue specimens. Consistent with
the above results, miR-143-3p was downregulated in pri-
mary tumor tissue specimens compared with the normal
controls (Fig. 1b).
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Correlations between miR-143-3p expression and
clinicopathological characteristics of ESCC
We next addressed the clinical significance of miR-143-3p
downregulation in ESCC by evaluating correlations be-
tween miR-143-3p expression level and clinicopathologi-
cal features in the 80 patients examined. Downregulation
of miR-143-3p significantly correlated with advanced clin-
ical stage and lymph node metastasis, while no significant
correlations were observed for other clinicopathological
parameters (Table 2). Additionally, patients with low levels
of miR-143-3p expression had a poorer overall survival
than those with high miR-143-3p expression (Fig. 1c). We
then evaluated whether miR-143-3p could serve as an in-
dependent prognostic factor by performing univariate and
multivariate analyses by the Cox proportional hazards
model. Table 3 shows that miR143-3p expression level,
clinical stage, and tumor differentiation all function as in-
dependent prognostic factors for these ESCC patients.
Taken together, these results suggest that the downregula-
tion of miR-143-3p may play an important role in the
development and progression of ESCC.
MiR-143-3p inhibits proliferation, migration, and invasion
in ESCC cells
We explored the potential biological function of miR-
143-3p in ESCC by stably-transfecting miR-143-3p and
anti-miR-143-3p expression constructs in ESCC cell lines.
Successful expression of miR-143-3p in stable transfectants
was confirmed by real time RT-PCR (Fig. 2a). Overexpres-
sion of miR-143-3p decreased ESCC cells proliferation, as
Fig. 1 MiR-143-3p is downregulated in ESCC cell lines and tumor tissue, and is associated with poor prognosis. a Real time RT-PCR analysis of three
most differentially downregulated miRNAs expression in four human ESCC cell lines and the normal esophageal epithelial cell line (HEEC). b Real time
RT-PCR analysis of miR-143-3p expression in 80 human ESCC tissue samples and their matched normal tissues. Expression levels are
shown in log2 scale. c Correlation between miR-143-3p expression and the overall survival of ESCC patients. Results are expressed as the
mean ± SD of three independent experiments. *: P <0.05; **: P <0.01
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shown by MTT assays (Fig. 2b) and colony formation
(Fig. 2c). Conversely, downregulation of miR-143-3p
promoted colony-formation efficiency and cell survival
(Fig. 2b, and d). Additionally, overexpression of miR-
143-3p resulted in a significant increase in Annexin-V
positive cells, whereas inhibition of miR-143-3p expres-
sion reduced apoptosis (Fig. 2e–f ).
We next investigated the influence of miR-143-3p
on tumor invasion and metastasis. The wound heal-
ing assay demonstrated that the migratory ability of
ESCC cells stably transfected with miR-143-3p was
significantly lower than that of cells transfected with
miR-NC (Fig. 3a). We then investigated whether cell
mobility suppression was simply the product of an
inhibitory effect on tumor cell growth, by performing
an invasion assay finding that miR-143-3p sup-
pressed the invasive ability of ESCC cells. Similarly,
cell invasion was reduced in miR-143-3p-transfected
cells as determined by the matrigel invasion assay
(Fig. 3b). These results indicate that miR-143-3p
could effectively suppress the growth, migration and
invasion of ESCC cells in vitro.
QKI is a potential target of miR-143-3p
We next investigated the mechanisms by which miR-
143-3p inhibits ESCC cell proliferation, migration, and
invasion, and five genes were selected as potential
targets of miR-143-3p based on analyses of publicly-
available databases. Among these genes, QKI exhibited
obviously upregulaed in ESCC cell lines (Additional
file 1: Figure S1). Moreover, we used a dual-luciferase
reporter system to demonstrate that miR-143-3p binds
directly to the 3’-UTR of QKI (Fig. 4a). Co-transfection
with miR-143-3p-expressing vector significantly inhibited
luciferase activity driven by the reporter vector containing
the wild-type QKI 3’-UTR but not the mutant 3’-UTR.
Furthermore, overexpression of miR-143-3p decreased
QKI protein levels in ESCC cells, while downregulation of
endogenous miR-143-3p increased QKI protein expres-
sion (Fig. 4b). These results demonstrate that miR-143-3p
suppressed the expression of QKI in ESCC by directly
targeting the QKI 3’-UTR.
The association between miR-143-3p and QKI was
further investigated by measuring levels of QKI
mRNA and protein in the primary ESCC samples
and also the cell lines using real time RT-PCR and
Table 2 Correlation between miR-143-3p expression and
clinicopathological features
Patient characteristics MiR-143-3p expression X2 P value




< 60 34 21(38.9 %) 13(50 %)
≥ 60 46 33(61.1 %) 13(50 %)
Gender 3.242 0.072
Female 18 9(16.7 %) 9(34.6 %)
Male 62 45(83.3 %) 17(65.4 %)
Tumor location 0.608 0.738
Upper 12 7(13 %) 5(19.2 %)
Middle 34 23(42.6 %) 11(42.3 %)
Lower 34 24(44.4 %) 10(38.5 %)
Histological grade 0.547 0.761
Poor 33 22(40.7 %) 11(42.3 %)
Moderate 31 20(37.0 %) 11(42.3 %)
Well 16 12(22.2 %) 4(15.4 %)
pT status 1.6222 0.444
pT1 12 10(18.5 %) 2(7.7 %)
pT2 25 16(29.6 %) 9(34.6 %)
pT3 43 28(20.2 %) 15(57.5 %)
Lymph node metastasis 4.297 0.038*
Absent (0) 33 18(33.3 %) 15(57.5 %)
Present (1/2/3) 47 36(66.7 %) 11(42.3 %)
TNM stage 4.941 0.026*
I/II 38 21(38.9 %) 17(65.4 %)
III 42 33(61.1 %) 9(34.6 %)
* p <0.05
Table 3 Univariate analysis and multivariate analysis for prognostic factors in ESCC patients
Variables Univariate analysis Multivariate analysis
P value HR 95 % CI P value
Age (<60/≥60) 0.346 - - -
Gender (Female/Male) 0.22 - - 0.785
Tumor location (Upper/Middle/Lower) 0.315 - - -
Clinical stage (I + II/III) <0.001* 2.378 1.061–5.330 0.035*
Histological grade (Well/moderate/Poor) 0.045* 0.521 0.344–0.788 0.02*
Lymph node metastasis (Present/Absent) <0.001* 1.96 0.845–4.547 0.117
MiR-143-3p expression (Low/High) <0.001* 0.367 0.171–0.786 0.01*
HR hazard ratio; 95 % CI 95 % confidence interval, *p < 0.05
He et al. Molecular Cancer  (2016) 15:51 Page 6 of 17
immunohistochemical staining. Figure 4c–d reveals
that the expression levels of QKI mRNA were signifi-
cantly higher in ESCC tumor tissues and cells
compared with normal tissue and control cells,
respectively. And among 80 ESCC samples, 62 were
positive for QKI protein and 18 were negative. It is
noteworthy that the expression levels of QKI protein
were significantly higher in tumor tissues than in
Fig. 2 MiR-143-3p has a strong tumor suppressive effect on ESCC cells growth in vitro. a Real time RT-PCR analysis of the relative expression of
miR-143-3p in each group of stably-transfected ESCC cells. b–d Colony formation and MTT assays in ESCC cells overexpressing or underexpressing
miR-143-3p. e–f Flow cytometric analysis of Annexin V-FITC staining was used to quantify apoptosis induced by miR-143-3p. Results are expressed
as the mean ± SD of three independent experiments. *: P <0.05;**: P <0.01
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matched adjacent normal tissues (Fig. 4e). Further-
more, the inverse association between miR-143-3p
and QKI was significant based on linear regression
analysis (Fig. 4f ).
We next investigated which of the QKI splice variants is
important for miR-143-3p-mediated tumor-suppression
by further analyzing the mRNA expression levels of
QKI-5, QKI-6, and QKI-7 in cells. Overexpression of
miR-143-3p markedly downregulated QKI-5 mRNA
expression, whereas miR-143-3p downregulation in-
creased QKI-5 mRNA expression (Fig. 4g). Collect-
ively, these results suggest that the tumor suppressive
effect of miR-143-3p occurred via suppression of QKI-
5 expression.
Effects of QKI-5 on ESCC cell proliferation, colony
formation, migration, and invasion in vitro
We next performed functional studies using cells sta-
bly transfected with pLenti QKI-5 and pLenti siQKI-5
to stably overexpress or deplete QKI-5, respectively.
QKI-5 upregulation significantly promoted ESCC cell
viability and colony formation (Fig. 5a and b), while
silencing of QKI-5 expression suppressed cell growth
(Fig. 5b and c). Additionally, downregulation of QKI-
Fig. 3 MiR-143-3p suppresses the migration and invasion of ESCC cells in vitro. a Wound-healing assay showed that ectopic expression of
miR-143-3p effectively suppressed cell motility. b Migration assay and Invasion assay revealed that the ectopic expression of miR-143-3p inhibited the
invasion ability of ESCC cells. Results are expressed as the mean ± SD of three independent experiments. *: P <0.05; **: P <0.01
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Fig. 4 MiR-143-3p negatively regulates the expression of QKI by directly targeting the QKI 3’-UTR. a Luciferase activity in cells following co-transfection
with control or miR-143-3p-encoding plasmids and wild-type or mutant-type pMIR vectors harboring the predictive miR-143-3p binding
site in the 3’-UTR of QKI. b Western blot analysis showed that miR-143-3p could inhibit the protein expression of ESCC cells. c Real time
RT-PCR analysis of QKI expression in human ESCC tissue samples and their matched normal tissues from ESCC patients (n = 80). Expression
levels are shown using a log2 scale. d RT-PCR analysis of QKI mRNA expression in ESCC cells compared with that in the normal esophageal
epithelial cell line (HEEC). e Immunohistochemical staining of QKI protein in primary ESCC tissue samples (Left: ×100; Right: ×200). f Analysis of correlation
between QKI and miR-143-3p expression levels in 80 pairs of ESCC tissue specimens. g RT-PCR analysis of the expression of the major QKI splice variants
regulated by miR-143-3p. Values are mean ± SD; *: P <0.05; **: P <0.01
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5 significantly increased apoptosis compared with the
control group (Fig. 5d).
We next determined whether QKI-5 could affect the
migration and invasion of ESCC cells. Wound healing
assay showed that downregulation of QKI-5 inhibited
the migratory activity of ESCC cells (Fig. 6a). Meanwhile,
Invasion assay demonstrated that inhibition of QKI-5
expression reduced the invasiveness of ESCC cells
(Fig. 6b). Consistently, matrigel invasion assay identified
a significant reduction in cell invasion by pLenti siQKI-
5-transfected cells compared with control cells (Fig. 6b).
Taken together, these observations demonstrate that
QKI-5 can promote ESCC progression by enhancing cell
proliferation, invasion, and migration.
QKI-5 is involved in miR-143-3p-mediated regulation of
ESCC cell growth, apoptosis, migration, and invasion
We next investigated the mechanism underlying the tumor
suppressive effect of miR-143-3p and evaluated whether
QKI-5 is involved in this process by stably co-transfecting
Kyse70 and Eca109 cells with miR-143-3p-expressing and
pLenti QKI-5 constructs with full length QKI-5 or relevant
control. MTT and colony formation assays showed that
miR-143-3p overexpression decreased both cell growth rate
and colony formation ability, whereas co-transfection of
miR-143-3p and pLenti QKI-5 significantly blocked this
anti-growth effect (Fig. 7a and b). Consistently, Fig. 7c
reveals that apoptosis was significantly increased in
cells transfected with miR-143-3p or miR-143-3p/
pLenti-Blank compared with pLenti QKI-5-transfected
cells. Furthermore, migration and invasion analyses
demonstrated that cells co-transfected with miR-143-
3p and pLenti QKI-5 had increased migratory and in-
vasive capacities compared with cells transfected with
miR-143-3p (Fig. 7d and e). These findings demon-
strate that QKI-5 is a functional target of miR-143-3p
and that ectopic expression of QKI-5 can reverse the
anti-tumor effect of miR-143-3p.
Fig. 5 Knockdown of QKI-5 inhibits ESCC cell growth and induces cell apoptosis. a, b Overexpression of QKI-5 led to stronger colony formation
ability and cell growth rate. b, c Downregulation of QKI-5 suppressed ESCC cell colony formation and proliferation ability. d Flow cytometric
analyses of Annexin V-FITC staining were used to quantify apoptosis rate induced by QKI-5. Values are the mean ± SD; *: P <0.05;**: P <0.01
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MiR-143-3p regulates tumor growth and apoptosis via
suppression of QKI-5 in vivo
We investigated the role of miR-143-3p in tumor growth
in vivo by subcutaneous injection of Kyse70 cells trans-
fected as described above into the flank of nude mice.
Figure 8a reveals that miR-143-3p overexpression signifi-
cantly reduced the growth rate, volume, and average
weight of Kyse70-derived tumors in mice. Furthermore,
histological analysis of tumor sections and found that
miR-143-3p-overexpressing cells exhibited increased
apoptosis compared with miR-NC cells. We further
examined the role of QKI-5 in tumor growth using
xenograft mouse models and found that downregulation
of QKI-5 attenuated the tumor growth rate and reduced
tumor volume in vivo. Additionally, restoration of QKI-5
promoted proliferation and significantly increased tumor
volume. Consistently, reduction of QKI-5 expression led
to increased apoptosis, whereas induction of QKI-5 obvi-
ously decreased apoptosis (Fig. 8b).
Furthermore, Fig. 8c shows that restoration of QKI-5
expression significantly reversed the suppression of
tumor growth induced by miR-143-3p. TUNEL analyses
also revealed that attenuation of apoptosis enforced the
expression of miR-143-3p and QKI-5. These observa-
tions clearly show that downregulation of miR-143-3p
plays an important role in ESCC growth in vivo by
targeting QKI-5.
MiR-143-3p/QKI-5 interaction regulates EMT in ESCC cells
EMT has received much attention concerning its role in
regulating invasion and metastasis in many cancers, in-
cluding ESCC. During EMT, epithelial cells lose expres-
sion of epithelial markers and acquire a mesenchymal
phenotype, resulting in enhanced invasion and metasta-
sis [19]. We detected the protein levels of EMT markers
in paired transfected cells to identify whether ESCC cells
exhibit EMT molecular marker changes. Figure 9a and b
demonstrate that both miR-143-3p overexpression and
Fig. 6 Knockdown of QKI-5 inhibits ESCC cell growth and motility in vitro. a Wound healing assays were used to evaluate the motility of ESCC
cells transfected with pLenti siQKI-5. b Migration assay and invasion assay were conducted in ESCC cells transfected with pLenti siQKI-5. Values
are the mean ± SD; *: P <0.05; **: P <0.01
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QKI-5 silening resulted in increased E-cadherin and β-
catenin protein levels and decreased of vimentin and N-
cadherin protein levels. Subsequently, we investigated
EMT-related protein expression after co-transfection to
explore whether QKI-5 cooperates with miR-143-3p to
modulate EMT. Notably, rescue experiments demon-
strated that miR-143-3p-dependent upregulation of epi-
thelial protein markers upregulation and downregulation
of mesenchymal protein markers was largely negated by
overexpression of QKI-5 (Fig. 9c). Furthermore, we mea-
sured expression levels of EMT proteins in ESCC cells in
vivo using immunohistochemistry analysis resected tumor
tissue sections. Consistently, staining of E-cadherin and β-
catenin protein was greatly increased in the miR-143-3p
and pLenti siQKI-5 transfected groups, whereas vimentin
and N-cadherin protein staining was diminished (Fig. 10a).
These studies show that both miR-143-3p induction and
QKI-5 suppression consistently led to stabilization of the
epithelial phenotype of ESCC cells. Similarly, E-cadherin
and β-catenin protein levels in the pLenti QKI-5 group
were decreased compared with the miR-143-3p group
(Fig. 10b). These results support a role for miR-143-3p/
QKI-5 axis in modulating EMT processing in ESCC
progression.
Discussion
MiRNAs are important post-transcriptional regulators of
gene expression and are involved in multiple biological
Fig. 7 Restoration of QKI-5 reverses miR-143-3p-mediated inhibition of ESCC cell growth and metastasis. a, b MTT and colony formation assays were
conducted to evaluate the proliferative capacity of ESCC cells. c Flow cytometric analysis of Annexin V-FITC staining was used to quantify apoptosis rate
in miR-143-3p and miR-143-3p/pLenti QKI-5 group cells. d Migration and invasion assay were conducted in ESCC cells transfected with miR-143-3p or
co-transfected with pLenti QKI-5. e Wound healing assays were used to evaluate the motility of ESCC cells transfected with miR-143-3p alone or
co-transfected with pLenti QKI-5. Results are expressed as the mean ± SD of three independent experiments. *: P <0.05;**: P <0.01
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Fig. 8 MiR-143-3p inhibits ESCC cells growth by inhibiting QKI-5 in vivo. a Effects of miR-143-3p on tumor growth in nude mice. Growth curves
and weights of tumors resulted from injection of Kyse70 cells stably expressing with miR-143-3p in nude mice. Apoptosis was evaluated by
performing a TUNEL assay using sections of the transplanted tumors (×200). b Effect of QKI-5 on tumor growth in nude mice. Xenograft assay
with Kyse70 stable cells revealed that inhibition of QKI-5 decreased the volume of the xenograft tumors, while restoration of QKI-5 showed a
proliferative tendency with significantly greater tumor volume. c Restoration of QKI-5 significantly reversed the suppression of tumor growth and
apoptosis induced by miR-143-3p. *: P <0.05; **: P <0.01
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processes, including tumorigenesis and metastasis. Al-
though miRNA functions not fully understood, miRNA
dysregulation plays a critical role in the initiation and
progression of multiple human cancers, by acting as
either oncogenes or tumor suppressors. In this study, we
evaluated the relationship between miR-143-3p expres-
sion levels and the clinicopathological features and out-
comes of ESCC patients. We report for the first time
that miR-143-3p acts as a tumor suppressor in the
development of ESCC by directly downregulating of
QKI-5 expression and inhibiting EMT in cancer cells.
Our findings indicate that miR-143-3p is potential ther-
apy for ESCC.
Previous studies have reported a tumor suppressor
role for miR-143 in several cancers. For example, miR-
143-3p is downregulated in bladder cancer and inhibits
cell growth through targeting oncogene KAS, but not
ERK-5 [20]. MiR-143 is also downregulated in cervical
Fig. 9 MiR-143-3p/QKI-5 interaction regulates EMT in ESCC cells. a, b Western blotting analysis of the protein levels of EMT markers in ESCC cells
after transfection with miR-143-3p or pLenti siQKI-5. c: Restoration of QKI-5 significantly reversed the suppression of EMT transition induced
by miR-143-3p
He et al. Molecular Cancer  (2016) 15:51 Page 14 of 17
cancer, enabling promotion of apoptosis and inhibition
of tumor formation through targeting of Bcl-2 [21]. Fur-
thermore, a recent report demonstrated that miR-143-
5p, another member of the miR-143 family, directly
targets COX-2 in gastric cancer to promote a greater
growth inhibitory effect and a higher apoptotic rate than
miR-143-3p [22]. Consistently, we found miR-143-3p to be
aberrantly downregulated in ESCC. Ectopic expression of
miR-143-3p significantly suppressed ESCC cells prolifera-
tion, induced apoptosis, and inhibited growth of xenograft
tumors in nude mice, indicating that miR-143-3p acts as a
tumor suppressor in ESCC. Furthermore, our research also
reveals that enforced expression of miR-143-3p effectively
represses cells migratory and invasive abilities.
We investigated the mechanisms underlying in miR-
143-3p induced inhibition of ESCC proliferation and me-
tastasis by conducting in silico analysis and dual-luciferase
reporter assay and identified QKI-5 as a direct down-
stream target gene of miR-143-3p. QKI is a member of
the signal transduction and activation of RNA (STAR)
Fig. 10 Immunohistochemistry analysis EMT markers expression in resected tumor tissue sections (×200). a: IHC analysis of the protein levels of
EMT markers in ESCC cells after transfection with miR-143-3p or pLenti siQKI-5 in mice. b: Restoration of QKI-5 significantly reversed the
suppression of EMT transition induced by miR-143-3p in mice
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family, and affects pre-mRNA splicing [23], mRNA turn-
over [24] and translation [25]. QKI is implicated in
diseases including ataxia, schizophrenia, inflammation,
and multiple cancers [26–29]. Additionally, QKI is associ-
ated with tumor initiation and progression, acting as a
tumor suppressor gene under the direct control of p53 in
glioblastoma multiforme [30]. Levels of QKI expression
are significantly decreased in some cancer tissues. For ex-
ample, QKI expression correlates well with the clinico-
pathologic characteristics and prognosis of gastric cancer,
with reduced proliferation of GC cells in vitro associated
with overexpression of QKI [31]. Furthermore, QKI-5 iso-
form has also been identified as a tumor suppressor in
oral squamous cell carcinoma [32], prostate cancer [16]
and lung cancer [33]. Contrasting with these observations
in other cancer types, our data demonstrate dramatic
upregulattion of QKI in ESCC tissues and cell lines, and a
correlation between QKI expression levels and tumor
metastasis and prognosis in ESCC patients. Disrupting
QKI expression, especially the QKI-5 isoform, also inhib-
ited ESCC cells proliferation and induced cell apoptosis in
vitro. Furthermore, the inhibitory effects of miR-143-3p
on ESCC cell proliferation, migration, and invasion were
reversed by restoration of QKI-5 expression, demonstrat-
ing the important contribution of QKI-5 in responses
triggered by miR-143-3p.
Gene dysregulation plays a critical role in the initiation
and progression of multiple human cancers. And many
genes are identified to have dual roles as either onco-
genes or tumor suppressors in different cancers. For
example, hyperactive STAT3 is thought to be oncogenic
in many cancers, and targeting IL-6/STAT3 is now a
therapy for cancer treatment. However, a recent study
revealed that STAT3 regulated ARF expression and sup-
pressed prostate cancer metastasis. Similarly, although
QKI-5 was characterized as a tumor suppressor in several
cancers, its role in ESCC has not been clarified. According
to our results we consider that QKI-5 may exert an onco-
genic function in ESCC. We think our findings challenge
the current discussion of the role of QKI-5 in tumor pro-
gression, further explorations will be made on the mecha-
nisms and pathways of QKI-5 in ESCC progression.
We also assessed the expression levels of EMT regula-
tory proteins in ESCC cells because many cancers arise
from epithelial cells and need to undergo EMT to become
invasive and metastasize. Notably, levels of N-cadherin
and vimentin were dramatically decreased in miR-143-3p
and pLenti siQKI-5 transfected cells. Meanwhile, levels of
the epithelial markers E-cadherin and β-catenin were in-
creased in both groups of transfected cells. Consistently,
the suppressive effect of miR-143-3p on EMT regulatory
proteins could be rescued by co-transfection with pLenti
QKI-5. Thus, the tumor suppressive role of miR-143-3p
may regulate the EMT pathway in ESCC.
Our research reveals that miR-143-3p expression is
downregulated in ESCC tissues and cells and inversely
correlates with clinical TNM stage and lymph node
metastatic status. Additionally, our in vivo and in vitro
experiments demonstrate that enforced expression of
miR-143-3p induces apoptosis, and suppresses cell pro-
liferation, migration, and invasion capabilities by target-
ing QKI-5 in ESCC cells. Our results identify a novel
tumor suppressive mechanism in ESCC, indicating that
miR-143-3p may serve as a new diagnostic and prognos-
tic biomarker for ESCC patients. Further studies in
ESCC are required to more coherently define the role of
this miR-143-3p-mediated molecular pathway in regulat-
ing ESCC initiation and progression.
Conclusions
This study demonstrates that miR-143-3p exhibits a
strong tumor-suppressive effect by inhibiting the expres-
sion of QKI-5. Furthermore, dysregulation of miR-143-3p
is a molecular mechanisms involved in the development
and progression of ESCC.
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